There’s no question, however, that the decision to abandon the twice-daily version introduces a significant delay to Pfizer’s plans to enter the obesity market, which has been transformed in ...

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category ... it had decided to drop the twice-daily version, after seeing ...

The drugmaker Pfizer is no longer developing a daily anti-obesity pill, setting back efforts to ... Pfizer said in late 2023 that it would abandon a twice-daily version of danuglipron that had ...

In December 2023, Pfizer scrapped development of a twice-daily danuglipron drug because ... "As a convenient once-daily pill, orforglipron may provide a new option and, if approved, could be ...

plus money-saving tips with our free twice-daily newsletter Sign up More than 50% of over-25s worldwide will be overweight or obese by 2050, according to The Lancet. With obesity-related illnesses ...

Pfizer (NYSE: PFE) is certainly in that group. However, the company finds itself at a distinct disadvantage after it recently threw in the towel on experimental obesity pill danuglipron because of ...

Altimmune and Viking Therapeutics have promising obesity drugs and could be great acquisition targets for Pfizer. Pfizer should be able to easily fund an acquisition of either small drugmaker.

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after the failure of its obesity pill. The New York City-based drugmaker’s ...